MyHealthChecked PLC - Half-year Report
MyHealthChecked PLC
("MyHealthChecked", "MHC" the "Group" or the "Company")
Half-Year Report
MyHealthChecked PLC, the consumer home-testing healthcare company, announces its unaudited half-year report for the six months ended
Financial highlights
· Revenue of
· Adjusted EBITDA loss
· Cash balances of
Commercial and operational highlights
· The Company signed a partnership agreement with Patients Know Best ("PKB") to enable customers using at-home blood and DNA tests from MHC to access their laboratory test results via the NHS App
· MHC became the exclusive supplier of PocDoc into Boots, which was added to the boots.com range in
· Signed agreement with Boots for the supply of a range of lateral flow self-tests and laboratory tests under the Boots' Own Brand ("OB") label
· End-customer purchases of wellness tests performed well- 45% volume increase year-on-year
· Phlebotomy kits registered in the
"As a Board we believe in the positive long-term growth potential for our wellness product range, but acknowledge that the category is still in its infancy and that awareness amongst potential end-users is currently limited.
"As an organisation with deep retail product knowledge, we have built a number of partnerships to support our retail engagement in the home-testing market. In particular, with Boots we are working with a trusted established retail organisation, with both digital reach and a bricks and mortar footprint, and we believe this is key to unlocking revenue potential in the
|
MyHealthChecked PLC |
||
|
Penny McCormick, Chief Executive Officer |
via Walbrook PR |
|
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
|
|
|
|
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
|
|
|
|
|
|
|
|
|
Walbrook PR Ltd (Media & IR) |
Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com |
|
|
|
Mob: +44(0)7980 541 893 / +44(0)7407 804 654 |
|
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in
MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests are made available through MHC online and through retail partners in-store and online.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare and proactive wellness in the growing at home testing kit market, with a focus on accessibility at the right price, led by
CHAIRMAN AND CEO JOINT STATEMENT
During the first half of 2025, the Board has been encouraged by the year-on-year growth in end-user sales for our Wellness portfolio which has now bedded-in at retailer-level. Internally, we have invested in the integration with Patients Know Best ("PKB") and have delivered to Boots UK Limited ("Boots") a full "Own Brand" testing portfolio the launch of which marks Boots' arrival as a key player in the home-testing space. Compliance has continued to drive the culture within our organisation as we cement our reputation as a solid, trusted and reliable partner with established expertise within the retailer home-testing space.
Business Review
Boots Own Brand
During the period under review we have continued to prioritise our collaboration with Boots, a partnership that enables MHC to play a pivotal role in the transformation of accessible healthcare, at a time of significant shifts in consumer demand and purchasing behaviour. Since the launch of COVID testing in
As previously reported on
MHC Wellness Portfolio
Sales of the MHC wellness range increased significantly in 2025 over the comparable period in the prior year with unit sales to end users increasing by 45%, with the most significant growth being in the higher value blood tests where sales volumes increased by 72% versus the same period last year. We also participated in several retail promotional programmes some of which focused purely on testing as well as others that expanded promotional activity into the nutritional supplement category. These promotions have provided valuable feedback on customer behaviours and, as a consequence, we are becoming better informed about where the opportunities for future growth in retail lie. As reported previously on
COVID sales
As our key customer entered 2025 with high stock levels of COVID Lateral Flow Tests ("LFTs") sales of COVID LFTs during H1 amounted to £nil (six months ended
Patients Know Best
As previously reported on
Our goals when we defined MHC's testing strategy were firstly, to prioritise the retail market to maximise availability and awareness of product and service, and secondly, to drive towards integration with the NHS to maximise the benefits of ownership and accessibility of personal health data, whilst aligning with the NHS 10-year plan for a unified patient health record. Our partnership with PKB has taken us further towards this second goal of data accessibility, and has strengthened our position as a trusted partner in customers' healthcare journeys, enabling us to work with Boots and PKB to drive as much uptake as possible by highlighting the options to upload their test results via PKB to the NHS app, which has achieved tens of millions of downloads since launch.
PocDoc
The launch of PocDoc by Vital Signs Solutions Limited earlier this year has further paved the way for greater patient accessibility and control over their critical health markers. With the Heart Health cholesterol test now launched, we are gearing up for future product launches of the connected self-tests, which are used within the NHS in selected health trusts. MHC is the exclusive supplier of this product into Boots, which was added to the boots.com range in
Other Developments
Alongside our delivery on specific commercial projects, we have continued to evolve our propriety digital platform to maximise scalability and resilience, and we have upgraded our infrastructure to simplify future integrations with third parties as and when they are required. We have also introduced automated testing which accelerates the introduction of new features and enhancements, improves quality control, and minimises the risk of errors. Our investment continues to strengthen the delivery of a consistently reliable and trusted customer experience.
Cyber security controls and data and information security management are also high up on the team's agenda day to day, and in the past two years we have achieved Cyber Essentials Plus and ISO 27001 accreditations, which we successfully transitioned to the new ISO 27001:2022 in
Financial performance
Sales for the six months ended
Gross margin for the six months ended
Total spend on the development and maintenance of IT infrastructure during the year to date amounted to
Other overheads were broadly in line with the prior year due to the continued focus on tight cost control. Sales and marketing costs increased from
Adjusted EBITDA is calculated as follows:
|
|
Unaudited £'000 |
|
Unaudited £'000 |
Audited £'000 |
|
Operating loss |
(1,438) |
|
(1,348) |
(2,230) |
|
Depreciation, amortisation and (profit)/loss on disposal |
127 |
|
119 |
249 |
|
Termination costs |
66 |
|
- |
- |
|
Share based payments |
15 |
|
30 |
54 |
|
Adjusted EBITDA |
(1,230) |
|
(1,199) |
(1,927) |
As previously reported, the Company submitted a claim to HMRC for the repayment of VAT levied on certain COVID PCR tests sold in earlier years. As certain elements of the claim have been accepted exceptional income of
At
Current trading and outlook
As a Board we believe in the positive long-term growth potential for our wellness product range, but acknowledge that the category is still in its infancy and that awareness amongst potential end-users is currently limited.
As an organisation with deep retail product knowledge, we have built a number of partnerships to support our retail engagement in the home-testing market. In particular, with Boots we are working with a trusted established retail organisation, with both digital reach and a bricks and mortar footprint, and we believe this is key to unlocking revenue potential in the
As always, I would like to thank our investors for their continued loyalty and support, and our talented executive team and valued external partners who have consistently developed excellence as we strive to secure a valuable place in the future of accessible, preventative wellness.
Chairman Chief Executive Officer
Consolidated statement of comprehensive income
For the 6 months ended
|
|
|
Unaudited 6 months ended 30 June 2025 |
Unaudited 6 months ended 30 June 2024 |
Audited Year ended |
|
|
Notes |
£'000 |
£'000 |
£'000 |
|
|
|
|
|
|
|
Revenue |
3 |
494 |
881 |
3,607 |
|
Cost of sales |
|
(766) |
(1,167) |
(3,801) |
|
Gross loss |
|
(272) |
(286) |
(194) |
|
|
|
|
|
|
|
Sales and marketing costs |
|
(317) |
(272) |
(627) |
|
|
|
|
|
|
|
Other administrative expenses |
|
(768) |
(760) |
(1,355) |
|
Termination costs |
|
(66) |
- |
- |
|
Share based payments |
|
(15) |
(30) |
(54) |
|
Administrative expenses |
|
(849) |
(790) |
(1,409) |
|
Operating loss |
|
(1,438) |
(1,348) |
(2,230) |
|
Exceptional Income |
|
- |
- |
206 |
|
Finance income |
|
82 |
150 |
239 |
|
Finance expense |
|
- |
(1) |
(1) |
|
Loss before and after income tax |
3 |
(1,356) |
(1,199) |
(1,786) |
|
|
|
|
|
|
|
Attributable to owners of the parent: |
|
(1,356) |
(1,199) |
(1,786) |
|
Loss per Ordinary Share - basic |
4 |
(2.62)p |
(2.31)p |
(3.45)p |
|
Fully diluted earnings per Ordinary Share |
4 |
(2.62)p |
(2.31)p |
(3.45)p |
Consolidated statement of financial position
As at 30 June 2025
|
|
|
Unaudited |
Unaudited |
Audited |
|
|
|
£'000 |
£'000 |
£'000 |
|
Non-current assets |
|
|
|
|
|
Property, plant and equipment |
|
52 |
66 |
82 |
|
Right-of-use assets |
|
- |
37 |
- |
|
Intangible assets |
|
1,296 |
1,420 |
1,353 |
|
Total non-current assets |
|
1,348 |
1,523 |
1,435 |
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
Inventories |
|
100 |
339 |
133 |
|
Trade and other receivables |
|
1,909 |
161 |
1,761 |
|
Cash and cash equivalents |
|
5,058 |
6,048 |
5,473 |
|
Total current assets |
|
7,067 |
6,548 |
7,367 |
|
|
|
|
|
|
|
Total assets |
|
8,415 |
8,071 |
8,802 |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
2,781 |
524 |
1,827 |
|
Lease liabilities |
|
- |
12 |
- |
|
Total liabilities |
|
2,781 |
536 |
1,827 |
|
|
|
|
|
|
|
Net assets |
|
5,634 |
7,535 |
6,975 |
|
|
|
|
|
|
|
Share capital |
|
781 |
780 |
781 |
|
Share premium |
|
3 |
- |
3 |
|
Employee Benefit Trust |
|
(25) |
(25) |
(25) |
|
Reverse acquisition reserve |
|
(6,044) |
(6,044) |
(6,044) |
|
Retained earnings |
|
10,919 |
12,824 |
12,260 |
|
Total equity |
|
5,634 |
7,535 |
6,975 |
Consolidated statement of changes in equity
For the 6 months ended
|
|
Share capital |
Employee Benefit Trust reserve |
Share Premium |
Reverse acquisition reserve |
Retained earnings |
Total |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
Equity as at |
780 |
(25) |
- |
(6,044) |
13,993 |
8,704 |
|
Loss for the year |
- |
- |
- |
- |
(1,786) |
(1,786) |
|
Total comprehensive loss |
- |
- |
- |
- |
(1,786) |
(1,786) |
|
Exercise of share options |
1 |
- |
3 |
- |
(1) |
3 |
|
Share-based payments |
- |
- |
- |
- |
54 |
54 |
|
Equity as at |
781 |
(25) |
3 |
(6,044) |
12,260 |
6,975 |
|
Loss for the period |
- |
- |
- |
- |
(1,356) |
(1,356) |
|
Total comprehensive loss |
- |
- |
- |
- |
(1,356) |
(1,356) |
|
Share-based payments |
- |
- |
- |
- |
15 |
15 |
|
Equity as at |
781 |
(25) |
3 |
(6,044) |
10,919 |
5,634 |
Consolidated statement of cash flows
For the 6 months ended
|
|
|
Unaudited 6 months ended 30 June 2025 |
Unaudited 6 months ended 30 June 2024 |
Audited Year ended |
|
|
|
£'000 |
£'000 |
£'000 |
|
|
Cash flows from operating activities |
|
|
|
|
|
Loss before taxation |
(1,356) |
(1,199) |
(1,786) |
|
|
Adjustments for: |
|
|
|
|
|
Depreciation and amortization |
127 |
124 |
255 |
|
|
Profit on sale of assets |
- |
(5) |
(6) |
|
|
Finance income |
(82) |
(150) |
(239) |
|
|
Finance expenses |
- |
1 |
1 |
|
|
Share-based payments |
15 |
30 |
54 |
|
|
Adjusted operating loss before changes in working capital |
(1,296) |
(1,199) |
(1,721) |
|
|
Changes in working capital |
|
|
|
|
|
Decrease in inventory |
33 |
3 |
209 |
|
|
(Increase)/decrease in trade and other receivables |
(148) |
3,499 |
1,907 |
|
|
Increase/(decrease) in trade and other payables |
954 |
(4,088) |
(2,785) |
|
|
Cash used in operations |
(457) |
(1,785) |
(2,390) |
|
|
Bank interest received |
82 |
149 |
230 |
|
|
Net cash outflow from operating activities |
(375) |
(1,636) |
(2,160) |
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
Proceeds from sale of fixed assets |
- |
10 |
10 |
|
|
|
Purchase of office equipment |
- |
(14) |
(31) |
|
|
Purchase of intangible assets |
(40) |
(47) |
(72) |
|
|
Net cash flows used in investing activities |
(40) |
(51) |
(93) |
|
|
Financing activities |
|
|
|
|
|
Exercise of share options |
- |
- |
3 |
|
|
Repayment of lease liability |
- |
(14) |
(26) |
|
|
Cash outflows from financing activities |
- |
(14) |
(23) |
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
(415) |
(1,701) |
(2,276) |
|
|
Cash and cash equivalents at the beginning of the period |
5,473 |
7,749 |
7,749 |
|
|
Cash and cash equivalents at the end of the period |
5,058 |
6,048 |
5,473 |
Notes to the unaudited interim financial information for the 6 months ended
1. General information
MyHealthChecked PLC (the "Group") is a public limited company incorporated and domiciled in England and Wales. The registered office of the Company is The Maltings,
The principal activity of the Group is in the development and commercialisation of diagnostic healthcare products.
2. Significant accounting policies
Basis of preparation
The interim financial information for the six months ended
These interim consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements.
The financial information presented is unaudited and has been prepared using the same accounting policies as those adopted in the financial statements for the year ended
The interim financial information includes unaudited comparative figures for the unaudited 6 months to
In the opinion of the Directors, the interim financial information for the period presents fairly the financial position and the results from operations and cash flows for the period.
Going concern
The interim financial statements have been prepared under the going concern basis as the Directors have undertaken a review of the future financing requirements of the ongoing operation of the Group and considers the Group is able to meet its working capital requirements.
3. Segment information
In the opinion of the directors, the Group has one class of business, being that of the provision of diagnostic healthcare products. All the segment assets associated with the provision of diagnostic healthcare products are located in the UK.
|
|
Unaudited £'000 |
Unaudited £'000 |
Audited £'000 |
|
COVID related products |
- |
572 |
2,881 |
|
Other |
494 |
309 |
726 |
|
Revenue from the provision of diagnostic healthcare products |
494 |
881 |
3,607 |
|
Loss from the provision of diagnostic healthcare products |
(1,092) |
(1,073) |
(1,698) |
|
Exceptional income |
- |
- |
206 |
|
Corporate costs |
(346) |
(275) |
(532) |
|
Net finance income |
82 |
149 |
238 |
|
Group loss before tax |
(1,356) |
(1,199) |
(1,786) |
|
|
|
|
|
|
Cash |
5,058 |
6,048 |
5,473 |
|
Segment assets |
3,295 |
1,961 |
3,289 |
|
Corporate assets |
62 |
62 |
40 |
|
Total assets |
8,415 |
8,071 |
8,802 |
|
Segment liabilities |
2,675 |
475 |
1,751 |
|
Corporate liabilities |
106 |
61 |
76 |
|
Total liabilities |
2,781 |
536 |
1,827 |
4. Loss per Ordinary Share
|
|
Unaudited |
Unaudited |
Audited |
|
Basic and diluted loss per Ordinary Share |
|
|
|
|
Loss for the period |
|
|
|
|
Weighted average number of shares - basic |
52,035,932 |
52,005,932 |
52,006,836 |
|
Less shares held by Employee Benefit Trust (weighted) |
(184,111) |
(184,111) |
(184,111) |
|
Weighted average no of shares |
51,851,821 |
51,821,821 |
51,822,725 |
|
Weighted average number of shares - fully diluted |
51,851,821 |
51,821,821 |
51,822,725 |
|
Loss per share - basic |
2.62p |
2.31p |
3.45p |
|
Fully diluted loss per share |
2.62p |
2.31p |
3.45p |
Basic loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares in issue during the period. Due to the loss in the six-month period ended
This interim financial statement will be released in accordance with the AIM Rules for Companies, and will be available shortly on the Company's website at https://investors.myhealthchecked.com/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE